CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.


Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable therapeutic responses and alternative therapies are needed for patients with unfavourable treatment outcomes after standard treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). One promising candidate is brentuximab vedotin, an antibody-drug… (More)
DOI: 10.1111/bjh.13085